Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 2
2017 4
2018 2
2019 1
2020 1
2021 4
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. O'Donnell PH, et al. Among authors: ramamurthy c. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369081 Free PMC article. Clinical Trial.
Reply by Authors.
Garg H, Psutka SP, Hakimi AA, Kim HL, Mansour AM, Pruthi DK, Liss MA, Wang H, Gaspard CS, Ramamurthy C, Svatek RS, Kaushik D. Garg H, et al. Among authors: ramamurthy c. J Urol. 2022 Sep;208(3):559. doi: 10.1097/JU.0000000000002829.02. Epub 2022 Sep 1. J Urol. 2022. PMID: 35942785 No abstract available.
Reply by Authors.
Garg H, Psutka SP, Hakimi AA, Kim HL, Mansour AM, Pruthi DK, Liss MA, Wang H, Gaspard CS, Ramamurthy C, Svatek RS, Kaushik D. Garg H, et al. Among authors: ramamurthy c. J Urol. 2022 Sep;208(3):560. doi: 10.1097/JU.0000000000002829.04. Epub 2022 Sep 1. J Urol. 2022. PMID: 35942787 No abstract available.
Managing adverse effects of immunotherapy.
Gerson JN, Ramamurthy C, Borghaei H. Gerson JN, et al. Among authors: ramamurthy c. Clin Adv Hematol Oncol. 2018 May;16(5):364-374. Clin Adv Hematol Oncol. 2018. PMID: 29851932 Review.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Milowsky MI, et al. Among authors: ramamurthy c. J Clin Oncol. 2024 Apr 20;42(12):1403-1414. doi: 10.1200/JCO.23.01547. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215355 Clinical Trial.
27 results